Molecular Signature That Determines the Acute Tolerance of G Protein-Coupled Receptors

Chengchun Min, Xiaohan Zhang, Mei Zheng, Ningning Sun, Srijan Acharya, Xiaowei Zhang and Kyeong-Man Kim*

Pharmacology Laboratory, College of Pharmacy, Chonnam National University, Gwangju 61186, Republic of Korea

Abstract
Desensitization and acute tolerance are terms used to describe the attenuation of receptor responsiveness by prolonged or intermittent exposure to an agonist. Unlike desensitization of G protein-coupled receptors (GPCRs), which is commonly explained by steric hindrance caused by the β-arrestins that are translocated to the activated receptors, molecular mechanisms involved in the acute tolerance of GPCRs remain unclear. Our studies with several GPCRs and related mutants showed that the acute tolerance of GPCRs could occur independently of agonist-induced β-arrestin translocation. A series of co-immunoprecipitations experiments revealed a correlation between receptor tolerance and interactions among receptors, β-arrestin2, and Gβγ. Gβγ displayed a stable interaction with receptors and β-arrestin2 in cells expressing GPCRs that were prone to undergo tolerance compared to the GPCRs that were resistant to acute tolerance. Strengthening the interaction between Gβγ and β-arrestin rendered the GPCRs more susceptible to tolerance. Overall, stable interaction between the receptor and Gβγ complex is required for the formation of a complex with β-arrestin, and determines the potential of a particular GPCR to undergo acute tolerance. Rather than turning off the signal, β-arrestins seem to contribute to continuous signaling when they are in the context of complex with receptor and Gβγ.

Key Words: GPCR, Acute tolerance, Desensitization, Gβγ, β-Arrestin, Dopamine D3 receptor

INTRODUCTION
Upon agonist stimulation, most GPCRs undergo conformational changes leading to the dissociation of Gα from Gβγ (Hepler and Gilman, 1992). Dissociated Gβγ potentiates receptor phosphorylation by mediating the association of GPCR kinase 2 (GRK2) with the plasma membrane, and activation of GRK2 by affecting the K_v and stoichiometry of phosphorylation (Benovic et al., 1986; Pitcher et al., 1992; Vickery and von Zastrow, 1999; Zheng et al., 2016). GRK2-mediated receptor phosphorylation increases the affinity of β-arrestins for receptors, and thereby uncouples the receptors from G proteins (Benovic et al., 1987; Lohse et al., 1990) or enhances receptor endocytosis (Ferguson et al., 1996).

Desensitization and tolerance of GPCRs are terms used to describe the attenuation of receptor responsiveness by prolonged or intermittent exposure to an agonist (Lohse et al., 1989; Hausdorff et al., 1990; Williams et al., 2013). Desensitization and acute tolerance of GPCRs have different temporal resolutions; i.e., desensitization is induced between seconds and minutes after agonist stimulation, whereas acute tolerance is induced between minutes and an hour (Williams et al., 2013). According to the current paradigm based on studies of the β2 adrenergic receptor (β2AR), receptor phosphorylation and β-arrestin translocation are suggested to be two key cellular events responsible for GPCR desensitization. β-Arrestins which are recruited to the activated receptors sterically interfere with the interaction between receptors and G proteins (uncoupling), resulting in a decrement of signaling efficiency. However, molecular mechanism of acute tolerance is yet not clear. Acute tolerance occurs over a longer period of time than desensitization, and its molecular mechanism should include desensitization and subsequent cellular events, such as endocytosis and recycling.

In preliminary studies with five GPCRs and related mutants with different tolerance properties, agonist-induced β-arrestin translocation that mediated desensitization did not explain the acute tolerance. The aim of the current study was to under-
stand whether common features or principles exist that can predict or explain the acute tolerance of GPCRs.

**MATERIALS AND METHODS**

**Materials**

Dopamine (DA), isoproterenol (ISO), (-)-quinpirole (Quin), forskolin, and antibodies against adrenalin and the FLAG epitope were obtained from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). [3H]-Sulpiride (84 Ci/mmol), [3H]-spiperone (85.5 Ci/mmol), and [3H]-CGP-12177 (41.7 Ci/mmol) were purchased from PerkinElmer Life Sciences (Boston, MA, USA). Antibodies against green fluorescent protein (GFP) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Human embryonic kidney (HEK-293) cells were obtained from the American Type Culture Collection (Rockville, MD, USA) and maintained in minimal essential medium supplemented with 10% (v/v) fetal bovine serum, 100 units/mL penicillin, and 100 µg/mL streptomycin in a humidified atmosphere containing 5% CO₂.

**DNA constructs**

Mammalian expression constructs for the human D₂ receptor (D₂R, short alternatively spliced form), D₃ receptor (D₃R), D₄ receptor (D₄R), β₁ adrenergic receptor (β₁AR), β₂AR, GRK2, and β-arrestin2 have been described previously (Kim et al., 2001; Cho et al., 2006). β-arrestin2-GFP, and the carboxyl terminus tail of GRK2 (GRK2-CT) were also described previously (Kim et al., 2001; Zheng et al., 2011), K149C-D₂R, S145/6A-D₃R, C147K-D₄R, Gβ1, and chimeric receptors between D₂R and D₃R (D₂R-[IL3-D₃R] and D₃R-[IL2-D₂R]) were prepared by site-directed mutagenesis or were described previously (Bizzozero, 1997; Robinson and Caron, 1997; Zheng et al., 2011; Min et al., 2013). All receptors and related constructs were tagged with FLAG or HA epitopes at the N-terminus. Some constructs were tagged with GFP at the carboxyl terminus tail.

**Reporter gene assay**

Cellular cAMP was measured by an indirect reporter gene method (Cho et al., 2010a; Zheng et al., 2011). Briefly, a reporter system with a plasmid containing the firefly luciferase gene under the control of multiple cAMP responsive elements, and with a pRL-TK control vector, was used. Transfected cells were seeded in 24-well plates, and each transfection set was organized into three identical groups. For D₂R, D₃R, and D₄R, cells were treated with 2 µM forskolin and Quin (10⁻⁷–10⁻⁵ M) for 4 h and harvested. Relative luciferase activity was measured using a dual luciferase assay kit (Promega, Madison, WI, USA). For β₁AR and β₂AR, cells were treated with increasing concentrations of ISO.

**Induction of tolerance**

Tolerance was induced as described previously (Min et al., 2013). Cells expressing the corresponding GPCR were treated with agonist for 1.5 min (first treatment) to trigger tolerance, and washed five times with serum-free medium (5 min per wash) at 37°C to remove all of the receptor-bound agonist. Cells were then re-challenged with agonist to induce the second response. The occurrence of tolerance was determined by comparing the amplitudes of the second response from the cells pre-treated with vehicle or agonist in the first treatment step.

**Immunoprecipitation**

Immunoprecipitation was conducted as described previously (Zheng et al., 2016). Cells were lysed with RIPA buffer (150 mM NaCl, 50 mM Tris pH 8.0, 1% NP-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate [SDS]) for 1 h at 4°C with gentle mixing. A slurry of agarose beads coated with anti-FLAG antibodies (25 µL) was mixed with the supernatant for 2.3 h on a rotation wheel at 4°C. Beads were washed with washing buffer (50 mM Tris, pH 7.4, 137 mM NaCl, 10% glycerol, 1% NP-40) three times for 5 min each at 4°C. The resulting immunoprecipitates were separated by SDS-PAGE, transferred to a nitrocellulose membrane, and the membrane was blotted with antibodies to corresponding target proteins.

**Confocal microscopy**

One day after the transfection, cells were seeded onto the 35-mm confocal dishes, which contain a 1-cm well in the center sealed by glass coverslip on the bottom, and they were allowed to recover for 1 day. Then, the cells were examined with a TCS SPS/AOBS/Tandem laser scanning confocal microscope (Leica, Jena, Germany).

**Statistical analysis**

All results are expressed as means ± SEM. Dose-response curves with more than three experimental groups were compared via two-way analysis of variance (ANOVA) with Bonferroni post-hoc tests. Student's t-test was used for some results. p-values of less than 0.05 were considered significant.

**RESULTS**

**Rapid desensitization and acute tolerance are caused by different molecular mechanisms**

Dopamine D₂ and D₃ receptors (D₂R, D₃R) show high homology in amino acid composition (46% overall amino acid homology and 78% identity in the transmembrane domain) (Giros et al., 1990) and share most of their signaling pathways (Cho et al., 2010b). Nevertheless, D₂R and D₃R display different intracellular trafficking properties and employ different regulatory mechanisms for given signaling pathways (Cho et al., 2007). It was reported that D₂R but not D₃R is phosphorylated in response to agonist stimulation (Kim et al., 2001). Similarly, β-arrestin translocation was observed in cells expressing D₂R but not D₃R (Fig. 1A), suggesting that D₂R but not D₃R would undergo desensitization. If the same molecular mechanism is involved in the development of desensitization and acute tolerance, D₂R but not D₃R is expected to undergo tolerance. As shown in Fig. 1B, D₂R but not D₃R showed tolerance.

Results in Fig. 1A and 1B suggest that molecular mechanisms other than β-arrestin translocation could be involved in the development of acute tolerance of GPCRs. To determine whether this observation is generalizable, five different GPCRs (D₂R, D₃R, D₄R, β₁AR, β₂AR) were selected. In addition, five mutant receptors of D₂R and D₃R, in which the tolerance properties or β-arrestin translocation propensity were altered, were utilized. Using these receptors, the correlation between β-arrestin translocation and their acute tolerance was evaluated.

D₂R (Fig. 1B), β₁AR (Fig. 1E), β₂AR (Fig. 1F), a point mutant
Fig. 1. Characterization of acute tolerance of various GPCRs. (A) Visualization of β-arrestin2-GFP translocation in response to agonist activation of D2R or D3R in HEK-293 cells. Cells stably expressing D2R or D3R (2.5 and 3.3 pmol/mg protein, respectively) were transfected with 2 μg β-arrestin2-GFP per 100 mm culture dish. Cells were stimulated with 10 μM DA for 5 min. (B) Determination of tolerance development in cells expressing D2R and D3R. HEK-293 cells expressing D2R or D3R were pre-treated with either serum-free medium containing 100 μM ascorbic acid (Veh) or 10 μM DA dissolved in Veh for 5 min. Cells were washed five times with warm (37°C) serum-free medium and treated with increasing concentrations of Quin. The cellular levels of cAMP were then measured using the CRE-luciferase reporter gene assay. "Forsk" represents forskolin. **p<0.01, ***p<0.001 when the D3R/Veh group was compared with other experimental groups. (C) Cells expressing D3R, D3R-[IL2-D2R], or D3R-[IL3-D2R] were treated with 10 μM DA for 5 min to induce tolerance. The results for the Veh-treated group significantly differed from those for the DA-treated groups of D3R or D3R-[IL2-D2R] expressing cells at treatment concentrations between 10^-10^-10^-8 M (p<0.001). (D) Cells expressing D4R were treated with 10 μM DA for 5 min to induce tolerance. (E, F) Cells expressing either β1AR (E) or β2AR (F) were treated with vehicle (Veh) or 10 μM epinephrine (Epi) for 5 min, washed three times with serum-free media at 37°C, then treated with increasing concentrations of isoproterenol to obtain dose-response curves. The Veh group of β1AR was significantly different from the Epi group at treatment concentrations between 3×10^-7-3×10^-5 M (p<0.001). The results for the Veh group of β2AR significantly differed from those for the corresponding Epi group at treatment concentrations between 10^-6-3×10^-5 M (p<0.001). For (C-F) receptor expression levels were maintained between 1.5 and 2.5 pmol/mg protein.
Fig. 2. Relationship between receptor/β-arrestin interactions at the basal state and receptor tolerance. (A) HEK-293 cells were transfected with K149C-D2R together with GFP-β-arrestin2. Cells were treated with 10 μM DA for 5 min. Receptor expression level was 2.4 pmol/mg protein. (C-H) Cell lysates were immunoprecipitated with FLAG beads. Samples were analyzed on SDS-PAGE. Immunoprecipitates were immunoblotted with antibodies against FLAG; co-immunoprecipitates and lysates were immunoblotted with antibodies against β-arrestin2. All data represent results from three to seven independent experiments with similar outcomes. Receptor expression levels were maintained between 2.1 and 2.5 pmol/mg protein. (C) Cells were transfected with FLAG-tagged D2R or D3R along with β-arrestin2. Cells were treated with 1 μM DA for 5 min. Ratios of immunoprecipitation which were normalized to D2R, are: 1.0 ± 0.45, D2R/DA (-); 2.71±1.45, D2R/DA (+); 7.21 ± 3.15, D3R/DA (-); 6.82 ± 2.92, D3R/DA (+). The D2R/DA (-) group is significantly different from the D2R/DA (+) (p<0.05, n=7) and D3R groups (p<0.001, n=6). (D) Cells were transfected with FLAG-tagged D2R, D3R, or D4R along with β-arrestin2. Ratios of immunoprecipitation which were normalized to D2R, are: 1.0 ± 0.19, D2R; 7.2 ± 3.1, D3R; 8.8 ± 3.5, D4R. D2R is significantly different from other groups (p<0.01, n=3). (E) Cells were transfected with FLAG-tagged D2R, β1AR, or β2AR along with β-arrestin2. (Left panel) Ratios of immunoprecipitation which were normalized to D2R, are: 1.0 ± 0.13, β1AR (p<0.01, n=3). (Right panel) Ratios of immunoprecipitation which were normalized to D2R, are: 1.0 ± 0.12, D2R; 7.59 ± 2.33. β2AR is significantly different from β1AR group (p<0.01, n=3). (F) Cells were transfected with FLAG-tagged WT-D3R, C147K-D3R, or S145/6A-D3R at the ratio of 1:6:7, along with β-arrestin2. Ratios of immunoprecipitation which were normalized to WT-D3R, are: 1.0 ± 0.14, WT-D3R; 7.29 ± 2.31, K149C-D3R (p<0.01, n=3). (G) Cells were transfected with FLAG-tagged WT-D3R, C147K-D3R, or S145/6A-D3R at the ratio of 1:6:7, along with β-arrestin2. Ratios of immunoprecipitation which were normalized to WT-D3R, are: 1.0 ± 0.25, WT-D3R; 7.09 ± 0.04, C147K; 0.18 ± 0.03, S145/6A. The WT group is significantly different from the C147K (p<0.05, n=3) and S145/6A groups (p<0.01, n=3). (H) Cells were transfected with FLAG-tagged D2R, D2R-[IL2-D2R], D2R-[IL3-D2R], or D2R along with β-arrestin2. Ratios of immunoprecipitation which were normalized to D2R, are: 1.0 ± 0.14, D2R; 7.29 ± 2.31, IL2-D2R; 10.25 ± 3.25, D2R-[IL2-D2R], 8.21 ± 2.59, D2R-[IL3-D2R]. D2R is significantly different from the other groups (p<0.01, n=3).

https://doi.org/10.4062/biomolther.2016.193

242
of D2R within the second intracellular loop (K149C-D2R) (Min et al., 2013), and a chimeric D3R whose second intracellular loop was replaced with that of D2R (D3R-[IL2-D2R]) (Fig. 1C), all showed tolerance. D2R showed a noticeable agonist-induced β-arrestin translocation (Fig. 1A), but K149C-D2R showed negligible translocation (Fig. 2A). In addition, only negligible β-arrestin translocation was reported in cells expressing β-AR (Shinya et al., 2000) and D2R-[IL2-D2R] (Kim et al., 2001).

D3R (Fig. 1B), dopamine D3 receptor (D3R) (Fig. 1D), a point mutant of D3R within the second intracellular loop (C147K-D3R) (Min et al., 2013), and a chimeric D3R in which the third intracellular loop was replaced with that of D2R (D3R-[IL3-D2R]) (Fig. 1C), did not show tolerance. Of these receptors that did not undergo tolerance, D3R still mediated noticeable agonist-induced translocation of β-arrestin (Fig. 1A). However, only negligible β-arrestin translocation was observed or reported in cells expressing C147K-D3R (Fig. 2B), D2R (Cho et al., 2006), or D2R-[IL3-D2R] (Kim et al., 2001). These results are summarized in Table 1, and overall suggest that the agonist-induced translocation of β-arrestin, which is responsible for the development of desensitization of GPCRs, is not a determining factor for the acute tolerance of the GPCRs that were tested in this study. Thus, certain cellular processes other than β-arrestin translocation are likely to play a role in the development of tolerance.

### The basal interaction between receptors and β-arrestin2 does not determine acute tolerance of GPCRs

Our results showed that agonist-induced β-arrestin translocation does not properly explain acute tolerance, although Gβγ and β-arrestins are still involved in the acute tolerance of D2R (Min et al., 2013). Thus, we conducted a series of co-

---

**Table 1. Relationship between β-arrestin translocation and tolerance of GPCRs**

| Receptor | β-AR | β-AR | D3R | D2R | K149C-D2R | C147K-D2R | D2R-[IL2-D2R] | D2R-[IL3-D2R] |
|----------|------|------|-----|-----|-----------|-----------|-------------|-------------|
| Tolerance | ++++ | ++++ | -   | +++ | +/-       | +++       | -           | ++++        |
| β-Arrestin translocation | +   | ++++ | +++ | -   | +/-       | +         | -           | -           |

*+: Represents the extent of agonist-induced β-arrestin translocation or tolerance.
in the cells that express the GPCRs which are prone to undergo acute tolerance. These results suggest that the interaction between receptors and Gβγ could be closely related to the development of receptor tolerance.

Stable interaction between Gβγ and β-arrestin is observed in the cells that express the GPCRs which are prone to undergo acute tolerance

Next, interaction between Gβγ and β-arrestin2 was tested. There was a stronger interaction between Gβγ and β-arrestin in cells expressing the GPCRs that showed acute tolerance (D2R, βAR, K149C-D2R, D2R-[IL2-D2R]) than in cells expressing GPCRs that did not undergo acute tolerance (D2R, C147K-D2R, DR4) (Fig. 4). The results shown in Fig. 3 and 4 suggest that the presence of β-arrestin2 in the receptor-Gβγ complex determines the ability of a particular GPCR to undergo tolerance. These results are summarized in Table 2.

The N domain of β-arrestin2 is involved in its interaction with D2R in collaboration with Gβγ

Because the simultaneous interaction of each GPCR with Gβγ and β-arrestin was required for acute tolerance, we investigated whether each pair of proteins from the receptor-Gβγ-β-arrestin complex could interact independently, or whether all pairs interacted together.
Table 2. Relationship between receptor/ ARR, receptor/Gβγ, and Gβγ/ARR interactions at basal state and tolerance of GPCRs

| Receptor | β2AR | β2AR | K149C-D3R | D3R | D3R | C147K-D3R | D3R-(IL3-D3R) |
|----------|------|------|-----------|-----|-----|-----------|---------------|
| Tolerance | +++ | ++++ | +++ | +++ | - | +/- | - | + |
| Receptor/ARR | +++ | ++++ | +++ | +++ | + | ++++ | - | +++ |
| Receptor/Gβγ | +++ | ++++ | ++++ | +++ | - | +/- | - | - |
| Gβγ/ARR | +++ | ++++ | ++++ | +++ | + | +/- | - | - |

*: Represents the extent of agonist-induced tolerance, and immunoprecipitation between receptor and Gβγ, or between Gβγ and β-arrestin at basal state.

Fig. 5. Mutual requirement of Gβγ and β-arrestin2 for the interaction and tolerance of D3R. (A) Cells expressing D3R were transfected with β-arrestin2 and/or GRK2-CT. Cell lysates were immunoprecipitated with FLAG beads. Cell lysates were immunoprecipitated with FLAG beads. Samples were analyzed on SDS-PAGE. Immunoprecipitates were immunoblotted with antibodies against FLAG; co-immunoprecipitates were immunoblotted with antibodies against β-arrestin2. The ratios of pull-down are 5.49 ± 1.32, Mock; 1.02 ± 0.29, GRK2-CT (p<0.01, n=3). (B) Con-KD and β-arrestin1/2-KD cells expressing FLAG-D3R were transfected with YFP-Gβγ1. Cell lysates were immunoprecipitated with FLAG beads. Immunoprecipitates were immunoblotted with antibodies against FLAG; co-immunoprecipitates and lysates were immunoblotted with antibodies against GF. The ratios of immunoprecipitation are 5.71 ± 1.28, Con-KD; 0.51 ± 0.03, β-Arr-KD (p<0.01, n=3). (C) A GST pull-down assay was conducted to determine the requirement of β-arrestin for the interaction between the third cytoplasmic loop of D3R (IL3-D3R) and Gβγ. For production of GST fusion proteins, 0.5 mM of IPTG was added to the bacterial cultures containing each plasmid for 2 hrs. Bacterial cell lysates containing GST or GST-IL3-D3R (Zheng et al., 2011) were incubated with cell lysates from control knockdown (Con-KD) and β-arrestin1/2-KD cells that expressed YFP-Gβγ1. Lower panel shows an SDS-PAGE analysis of the afterwash of bacterial cell lysates. The ratios of pull-down are 3.39, Con-KD; 1.0, β-Arr-KD. The data represent results of two independent experiments with similar outcomes. (D) Interaction between β-arrestin2 and Gβγ was determined by a GST pull-down assay. Bacterial lysates containing the GST fusion proteins of the full-length (GST-β-arrestin2-FL), N-domain (GST-β-arrestin2-N), C-domain (GST-β-arrestin2-C), or C-domain plus carboxyl tail of rat β-arrestin2 (GST-β-arrestin2-CCT) (Zheng et al., 2011) were mixed with the cell lysates of HEK-293 cells transfected with YFP-Gβγ1. After three washes, GST beads were incubated with SDS sample buffer. The eluents were analyzed with SDS-PAGE and blotted with antibodies to GF (GST pull-down part). The figure in the lower panel shows the SDS-PAGE gel which contains ‘after-wash’ of bacterial cell lysates. The ratios of pull-down are 1.0, N-domain; 0.3, C-domain; 0.1, CCT domain. The data represent results of two independent experiments with similar outcomes. (E) Diagram showing the topology of the protein complex formed by D3R, Gβγ, and β-arrestin.

three binding partners were required. To test this possibility, interactions between D3R and Gβγ or β-arrestin2 were determined in the absence of either β-arrestin or Gβγ, respectively. When cellular Gβγ was sequestered by co-expression of GRK2-CT, the interaction between D3R and β-arrestin was abolished (Fig. 5A). In the reverse situation (Fig. 5B), the interaction between D3R and Gβγ was abolished when cellular β-arrestins were knocked down (Min et al., 2013). These results
were also confirmed by GST pull-down assays. Interaction between the third intracellular loop of D3R and Gβγ was inhibited when the expression of cellular β-arrestin was lowered (Fig. 5C). Overall, these results suggested that Gβγ and β-arrestin are mutually required for their interaction with D3R. In agreement with these results, receptors are able to associate with β-arrestins and Gβγ through distinct residues (Bornancin and Parker, 1997; Mahon et al., 2006). In addition, β-arrestins can interact with Gβ1 subunits (Yang et al., 2009) through residues that do not necessarily contribute to the association between Gβ1 and GPCRs (Shenoy and Lefkowitz, 2005; Mahon et al., 2006), thus allowing β-arrestins to associate simultaneously with GPCRs and the Gβγ dimer.

To determine the regions of β-arrestin2 that interact with Gβγ, β-arrestin2 was divided into three fragments, comprising its N-, C-, and CT-domains (Zheng et al., 2011), and GST pull-down assay was conducted for the interaction with Gβ1. As shown in Fig. 5D, the N-domain of β-arrestin2 and C-domain to a less extent interacted with Gβ1. These results suggested that the N-domain of β-arrestin2 mainly interacts with D3R in a Gβγ-dependent manner (Fig. 5E).

**Strengthening the interaction between Gβγ and β-arrestin enhances the acute tolerance of receptors.**

Our results suggested that basal interactions of each GPCR tested with Gβγ, as well as the interaction between Gβγ and β-arrestin, were correlated with acute tolerance. It was noticeable that D4R and D3R-[IL3-D3R], which did not undergo acute tolerance (Fig. 1C, 1D), had an abundant interaction with β-arrestin2 (Fig. 2D, 2H) but a weak interaction with Gβγ (Fig. 3A, 3B). In addition, a weak interaction was observed between Gβγ and β-arrestin2 in cells expressing these receptors (Fig. 4D). Therefore, we wanted to determine whether enforcement of the receptor/Gβγ/β-arrestin complex by strengthening the interaction between Gβγ and β-arrestin endowed GPCRs with the propensity to undergo acute tolerance. For this determination, we prepared a DNA sequence encoding the fusion protein Gβ1-Arr3 where β-arrestin2 was attached to the carboxyl tail of Gβ1.

Expression of Gβ1-Arr3, but not simultaneous expression of Gβ1 and β-arrestin2 in β-arrestin1/2-knockdown cells, rendered D3R prone to acute tolerance (Fig. 6A). Similar results were obtained with D3R-[IL3-D3R] (Fig. 6B). When this strategy was applied to D2R, which neither underwent tolerance nor was heavily bound to β-arrestin2, receptor tolerance was not induced (Fig. 6C). Thus, it could be postulated that the stable complex with Gβγ and β-arrestin is required for the development of receptor tolerance.

Overall, these results showed that the simultaneous interaction between the receptors, and both Gβγ and β-arrestin may be related to their acute tolerance properties.

**DISCUSSION**

Rapid desensitization and acute tolerance are usually distinguished based on the different time points when functional changes appeared after agonist treatment. Thus, proper establishment of time windows is needed to correctly determine the molecular mechanisms and functional consequences of rapid desensitization and acute tolerance.

While GRK2-mediated receptor phosphorylation and sub-

---

https://doi.org/10.4062/biomolther.2016.193

246
sequent β-arrestin translocation toward activated receptors are believed to be responsible for GPCR desensitization, recent studies of βAR suggest that this paradigm might need reinterpretation or correction. For example, knockdown of GRK2 or GRK6 resulted in a partial decrement of βAR tolerance, but did not affect the agonist-induced association between βAR and β-arrestin2 (Nobles et al., 2011). In addition, another study showed that GRK2 was not involved in the rapid desensitization of βAR (Violin et al., 2008). Thus, it is clear that β-arrestins are involved in both rapid desensitization and acute tolerance. On the other hand, more data are required to generalize the roles of GRK2 in the rapid attenuation of GPCR signaling.

Results in the current study show that β-arrestins are required for the interaction between Gβγ and D₃R, and that formation of a stable β-arrestin-receptor complex does not prevent, but rather favors, continuous signaling of D₃R. β-arrestins might have different roles in the regulation of GPCR signaling if they are in different contexts; for example, associated with Gβγ. For example, recent studies examining the parathyroid hormone receptor (PTHR) and vasopressin type 2 receptor (Feinstein et al., 2013; Wehbi et al., 2013) have shown that these receptors forms a ternary complex with β-arrestin2 and Gβγ, which enables more persistent signaling of the receptors through the Gq subunit.

Tolerance represents a gradual decrement of response to a drug treatment following its repeated use, thus increasingly larger doses are required to obtain similar therapeutic effects obtained by administration of initial dose. Compared to rapid desensitization, detailed molecular mechanism of acute tolerance is not clear. Thus, the present study has revealed that potentialities to undergo tolerance can be predicted. GPCRs have the tendency to undergo tolerance if they are predisposed to mediate the formation of a stable protein complex with β-arrestins and Gβγ.

CONFLICT OF INTEREST

The authors state no conflict of interest exists.

ACKNOWLEDGMENTS

This work was funded by KRF-2014R1A2A2A01002547. We thank the Korea Basic Science Institute for their technical support.

REFERENCES

Benovic, J. L., Kuhn, H., Weyand, I., Codina, J., Caron, M. G. and Lefkowitz, R. J. (1987) Functional desensitization of the isolated β-adrenergic receptor by the β-adrenergic receptor kinase: potential role of an analog of the retinal protein arrestin (48-kDa protein) Proc. Natl. Acad. Sci. U.S.A. 84, 8879-8882.

Benovic, J. L., Strasser, R. H., Caron, M. G. and Lefkowitz, R. J. (1986) β-adrenergic receptor kinase: identification of a novel protein kinase that phosphorylates the agonist-occupied form of the receptor. Proc. Natl. Acad. Sci. U.S.A. 83, 2797-2801.

Bizzozero, O. A. (1997) The mechanism and functional roles of protein palmitoylation in the nervous system. Neupediatrics 28, 23-26.

Bornancin, F. and Parker, P. J. (1997) Phosphorylation of protein kinase C-α on serine 657 controls the accumulation of active enzyme and contributes to its phosphatase-resistant state. J. Biol. Chem. 272, 3544-3549.

Cho, D., Zheng, M., Min, C., Ma, L., Kurose, H., Park, J. H. and Kim, K. M. (2010a) Agonist-induced endocytosis and receptor phosphorylation mediate desensitization of dopamine D2 receptors. Mol. Endocrinol. 24, 574-586.

Cho, D. I., Beom, S., Van Tol, H. H., Caron, M. G. and Kim, K. M. (2006) Characterization of the desensitization properties of five dopamine receptor subtypes and alternatively spliced variants of dopamine D2 and D3 receptors. Biochem. Biophys. Res. Commun. 350, 634-640.

Cho, D. I., Zheng, M. and Kim, K. M. (2010b) Current perspectives on the selective regulation of dopamine D2 and D3 receptors. Arch. Pharm. Res. 33, 1521-1538.

Cho, E. Y., Cho, D. I., Park, J. H., Kurose, H., Caron, M. G. and Kim, K. M. (2007) Roles of protein kinase C and actin-binding protein 280 in the regulation of intracellular trafficking of dopamine D2 receptor. Mol. Endocrinol. 21, 2242-2254.

Feinstein, T. N., Yui, N., Webber, M. J., Wehbi, V. L., Stevenson, H. P., King, D. J., Jr., Hallows, K. R., Brown, D., Bouley, R. and Vilardaga, J. P. (2013) Noncanonical control of vasopressin receptor type 2 signaling by retromer and arrestin. J. Biol. Chem. 288, 27849-27860.

Ferguson, S. S., Downey, W. E., 3rd, Colapietro, A. M., Barak, L. S., Menard, L. and Caron, M. G. (1996) Role of β-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science, 271, 363-366.

Giro, B., Martres, M. P., Sokoloff, P. and Schwartz, J. C. (1990) Gene cloning of human dopaminergic D2 receptor and identification of its chromosome. C. R. Acad. Sci. III, Vie 311, 501-508.

Hausdorff, W. P., Caron, M. G. and Lefkowitz, R. J. (1990) Turning off the signal: desensitization of β-adrenergic receptor function. FASEB J. 4, 2881-2889.

Hepler, J. R. and Gilman, A. G. (1992) G proteins. Trends Biochem. Sci. 17, 383-387.

Kim, K. M., Valenzano, K. J., Robinson, S. R., Yao, W. D., Barak, L. S. and Caron, M. G. (2001) Differential regulation of the dopamine D2 and D3 receptors by G protein-coupled receptor kinases and β-arrestins. J. Biol. Chem. 276, 37409-37414.

Lohse, M. J., Benovic, J. L., Codina, J., Caron, M. G. and Lefkowitz, R. J. (1990) β-Arrestin: a protein that regulates β-adrenergic receptor function. Science 248, 1547-1550.

Lohse, M. J., Lefkowitz, R. J., Caron, M. G. and Benovic, J. L. (1989) Inhibition of β-adrenergic receptor kinase prevents rapid homologous desensitization of β-adrenergic receptors. Proc. Natl. Acad. Sci. U.S.A. 86, 3011-3015.

Mahon, M. J., Bonacci, T. M., Divieti, P. and Smrcka, A. V. (2006) A docking site for G protein βγ subunits on the parathyroid hormone 1 receptor supports signaling through multiple pathways. Mol. Endocrinol. 20, 136-146.

Min, C., Zheng, M., Zhang, X., Caron, M. G. and Kim, K. M. (2013) Novel roles for β-arrestins in the regulation of pharmacological sequestration to predict agonist-induced desensitization of dopamine D2 receptors. Br. J. Pharmacol. 170, 1112-1129.

Nobles, K. N., Xiao, K., Ahn, S., Shukla, A. K., Lam, C. M., Rajagopal, S., Strachan, R. T., Huang, T. Y., Bressler, E. A., Hara, M. R., Shenoy, S. K., Gygi, S. P. and Lefkowitz, R. J. (2011) Distinct phosphorylation sites on the β2-adrenergic receptor establish a barcode that encodes differential functions of β-arrestins. Sci. Signal. 4, ra151.

Pitchen, J. A., Inglese, J., Casey, J., Higgins, J. B., Arroja, J. L., Casey, P. J., Kim, C., Benovic, J. L., Kwarra, M. M., Caron, M. G. and Lefkowitz, R. J. (1992) Role of βγ subunits of G proteins in targeting the β-adrenergic receptor kinase to membrane-bound receptors. Science 257, 1264-1267.

Robinson, S. W. and Caron, M. G. (1997) Selective inhibition of adenyl cyclase type V by the dopamine D2 receptor. Mol. Pharmacol. 52, 508-514.

Shenoy, S. K. and Lefkowitz, R. J. (2005) Receptor-specific ubiquitination of β-arrestin directs assembly and targeting of seven-transmembrane receptor signalosomes. J. Biol. Chem. 280, 15315-15324.
Shiina, T., Kawasaki, A., Nagao, T. and Kurose, H. (2000) Interaction with β-arrestin determines the difference in internalization behavior between β1- and β2-adrenergic receptors. J. Biol. Chem. 275, 29082-29090.

Vickery, R. G. and von Zastrow, M. (1999) Distinct dynamin-dependent and -independent mechanisms target structurally homologous dopamine receptors to different endocytic membranes. J. Cell Biol. 144, 31-43.

Violin, J. D., Dipilato, L. M., Yildirim, N., Elston, T. C., Zhang, J. and Lefkowitz, R. J. (2008) β2-adrenergic receptor signaling and desensitization elucidated by quantitative modeling of real time cAMP dynamics. J. Biol. Chem. 283, 2949-2961.

Wehbi, V. L., Stevenson, H. P., Feinstein, T. N., Calero, G., Romero, G. and Vilardaga, J. P. (2013) Noncanonical GPCR signaling arising from a PTH receptor-arrestin-Gq1 complex. Proc. Natl. Acad. Sci. U.S.A. 110, 1530-1535.

Yang, M., He, R. L., Benovic, J. L. and Ye, R. D. (2009) β-arrestin1 interacts with the G protein subunits β1/2 and promotes β1/2-dependent Akt signaling for NF-κB activation. Biochem. J. 417, 287-296.

Zheng, M., Cheong, S. Y., Min, C., Jin, M., Cho, D. I. and Kim, K. M. (2011) β-arrestin2 plays permissive roles in the inhibitory activities of RGS9-2 on G protein-coupled receptors by maintaining RGS9-2 in the open conformation. Mol. Cell. Biol. 31, 4887-4901.

Zheng, M., Zhang, X., Guo, S., Zhang, X., Min, C., Cheon, S. H., Oak, M. H., Kim, Y. R. and Kim, K. M. (2016) Agonist-induced changes in RalA activities allows the prediction of the endocytosis of G protein-coupled receptors. Biochim. Biophys. Acta 1863, 77-90.